| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 2, 2026 | Dren Bio Announces $350 Million Financing |
SAN CARLOS, CA, Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics, announced the closing of an oversubscribed $350 million private financing.
>> Click here for more fundi... |
| Oct 30, 2026 | Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline | Dren Bio has closed an oversubscribed $350 million private financing to advance its lead antibody therapy dibotatug toward regulatory submission and commercialization while expanding its broader oncology and autoimmune pipeline. The financi... |
| Oct 26, 2026 | HBM Portfolio Company Lycia Therapeutics Raises USD 317.5 Million in Nasdaq IPO and Delivers Strong Market Debut | HBM Healthcare Investments today announced the successful initial public offering of its portfolio company Lycia Therapeutics (NASDAQ: LYCA). Lycia is a clinical-stage biotechnology company developing novel therapeutics designed to degrade ... |
| Aug 30, 2026 | Shape Memory Medical Raises $10 Million Led By August Global Partners To Advance Aortic Clinical Trials | Shape Memory Medical has closed a $10 million convertible note financing to advance clinical development of its shape memory polymer technology for aortic disease. New investor August Global Partners led the financing, with Taiwania Capital... |
| Jul 24, 2026 | Crystalys Therapeutics Announces $130 Million Series B Financing To Advance Gout Treatment Dotinurad | Crystalys Therapeutics announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 in... |
| Jul 22, 2026 | Crystalys Therapeutics Raises $130 Million To Bring Late-Stage Gout Drug To U.S. Market | Crystalys Therapeutics raises $130 million in an oversubscribed Series B financing round. The funding will help Crystalys take its late-stage gout drug to market. Series B comes less than a year after its impressive $205 million Series A of... |
| Jul 14, 2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension |
PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million.
>> Click here for more f... |
| Jul 11, 2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| Jul 10, 2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| Jul 8, 2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program
FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| Jul 8, 2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding.
The round was led by SR One, ... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75M in Series D Funding | Lycia Therapeutics, a South San Francisco, California-based developer of extracellular protein degradation and lysosomal targeting chimera (LYTAC) therapeutics, raised $75m in Series D funding.
The round was co-led by Janus Henderson Invest... |
| Jun 29, 2026 | Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline | Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included... |
| May 11, 2026 | CellCentric Secures $220M to Accelerate Myeloma Drug Inobrodib | CellCentric secured $220 million in Series D funding. This capital fuels pivotal clinical trials for inobrodib. Inobrodib is a novel oral p300/CBP inhibitor. It targets relapsed or refractory multiple myeloma. Phase 2 data demonstrated sign... |
| May 7, 2026 | CellCentric: $220 Million Series D Raised To Advance Inobrodib Trials For Multiple Myeloma | CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma.
The finan... |
| Jan 26, 2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding.
Backers included new investors includi... |
| Jan 26, 2026 | Corxel Raises Up to $287 Million In Series D1 To Advance Oral GLP 1 Program and Broader Cardiometabolic Pipeline | CORXEL Pharmaceuticals Limited said it has completed a Series D1 financing, raising up to $287 million to fund the development of CX11, its oral small molecule GLP-1 receptor agonist for obesity and overweight, as well as additional cardiom... |
| Jan 11, 2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| Jan 8, 2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing.
The round was co-led by RA Capital Management, Fidelity Ma... |
| Jan 8, 2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| Dec 17, 2025 | SK Capital Invests Big in Biopharma Powerhouse Swixx | SK Capital Partners acquired a majority stake in Swixx Biopharma AG, valuing the biopharma commercialization leader over EUR 1.5 billion. This strategic investment boosts Swixx's global expansion and growth in underserved pharmaceutica... |
| Dec 15, 2025 | SK Capital acquires majority stake in Swixx Biopharma at EUR 1.5 billion valuation |
HBM Healthcare Investments, an investment company focused on the healthcare sector, has announced the signing of a binding agreement to sell a majority stake in Swixx Biopharma. Swixx Biopharma has delivered exceptional growth, with revenu... |
| Dec 15, 2025 | SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion | SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioP... |
| Oct 23, 2025 | Electra Therapeutics: $183 Million Series C Raised To Advance SIRP-Targeted Therapies For Immune Disorders And Cancer | Electra Therapeutics, a clinical-stage biotechnology company pioneering therapies against novel targets in immunology and cancer, has announced the close of an oversubscribed $183 million Series C financing round. The round was co-led by Ne... |
| Oct 22, 2025 | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
Wed, Oct 22, 2025 13:10 CET Report this content
Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with seriou... |
| Oct 22, 2025 | Electra Therapeutics Raises $183M in Series C Funding | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, raised $183m in Series C financing.
The round was co-led by Nextech... |
| Jun 25, 2025 | Neuron23: Pioneering Precision Medicine with a $96.5 Million Boost | In the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici... |
| Jun 25, 2025 | Neuron23 Raises $96.5M in Series D Financing | Neuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding.
The round wa sled by heal... |
| Jun 24, 2025 | Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological Medicines | Neuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar... |
| May 28, 2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company... |
| May 23, 2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| Mar 18, 2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| Mar 18, 2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| Mar 17, 2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding.
The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| Jan 10, 2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| Jan 9, 2025 | Numab raises additional CHF50 million |
In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| Nov 21, 2024 | Bain Capital-backed 360 ONE Asset bets on CDMO player from TPG’s portfolio | Tarun Sharma, head of healthcare and consumer, 360 One Asset
360 ONE Asset, an asset management firm backed by private equity firm Bain Capital, has invested in TPG-backed contract drugmaker OneSource Specialty Pharma in a secondary transac... |
| Oct 16, 2024 | Swiss investor HBM leads funding in TPG-backed drugmaker at $1.65 bn valuation | Premium
Credit: 123RF.com
Swiss investment firm HBM Healthcare has led a Rs 801 crore ($95 million) funding round in an Indian contract drug manufacturing company that also counts private equity firm TPG as an investor. HBM and other invest... |
| May 3, 2024 | Karius Revolutionizes Infectious Disease Diagnostics with $100M Funding Boost | Karius, a genomic diagnostics powerhouse, has secured a whopping $100 million in Series C funding to expand its groundbreaking Karius Test. This test, a game-changer in infectious disease diagnosis, uses cutting-edge genomic analysis and AI... |
| May 2, 2024 | Karius Raises $100M in Series C Funding | Karius, Inc., a Redwood City, CA-based leader in genomic diagnostics for infectious disease, raised $100m in Series C funding.
The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare. Also investing was n... |
| Mar 28, 2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments announces the return of Dr Andreas Wicki; new investment of USD 12 million in ArriVent Biopharma | HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the inve... |
| Jan 21, 2022 | HBM Healthcare Investments : Quarterly Report December 2021 | Quarterly Report 2021
December
At a Glance
Profile and Portfolio
2
HBM Healthcare Investments invests in the human medicine, biotechnology, medical techno logy and diagnostics sectors and related areas. The company holds and actively manag... |
| Jan 21, 2022 | HBM Healthcare Investments Quarterly Report December 2021 | HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments Quarterly Report December 2021
21-Jan-2022 / 06:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible fo... |
| Jan 3, 2022 | HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021 | EQS-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021
03-Jan-... |
| Nov 8, 2021 | HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech | EQS Group-News: HBM Healthcare Investments AG / Key word(s): IPO HBM Healthcare Investments benefits from the IPO of portfolio company IO Biotech 2021-11-08 / 06:46
---------------------------------------------------------------------------... |
| Oct 22, 2021 | HBM Healthcare Investments : Half-year Report September 2021 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Half Year Results
HBM Healthcare Investments Half-year Report September 2021
22-Oct-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is ... |
| Oct 22, 2021 | HBM Healthcare Investments : Half-Year Report September 2021 | Half-Year Report2021
September
At a Glance
Profile and Portfolio
2
HBM Healthcare Investments invests in the human medicine, biotechnology, medical techno logy and diagnostics sectors and related areas. The company holds and actively manag... |
| Jun 25, 2021 | HBM Healthcare Investments : Successful IPO for HBM portfolio company Monte Rosa Therapeutics | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
Successful IPO for HBM portfolio company Monte Rosa Therapeutics
25-Jun-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely r... |
| Jun 21, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
HBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange
21-Jun-2021 / 06:45 CET/CEST
Release of an ad hoc announce... |
| Jun 21, 2021 | HBM Healthcare Investments : portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
HBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange
21-Jun-2021 / 06:45 CET/CEST
Release of an ad hoc announce... |
| Jun 21, 2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Ambrx Biopharma raises USD 126 million in initial public offering on New York Stock Exchange | Ambrx Biopharma (NYSE: AMAM), a private company in the portfolio of HBM Healthcare Investments, completed its initial public offering on the New York Stock Exchange last Friday. The company raised USD 126 million in new capital through the ... |
| Jun 15, 2021 | HBM Healthcare Investments : announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Bond
HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million
15-Jun-2021 / 07:00 CET/CEST
Release of an ad h... |
| Jun 15, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Bond
HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million
15-Jun-2021 / 07:00 CET/CEST
Release of an ad h... |
| Jun 15, 2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a minimum issue amount of CHF 60 million | HBM Healthcare Investments Ltd announces the issue of a bond with a 6-year term and a nominal amount of CHF 60 million with the possibility to increase the issue amount up to a maximum of CHF 75 million. The proceeds will be used to refinan... |
| Jun 9, 2021 | HBM Healthcare Investments : portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Merger
HBM portfolio company Valo Health and Khosla Ventures Acquisition Co. to combine and create publicly traded company
09-Jun-2021 / 18:51 CET/CEST
Release of an ad hoc anno... |
| May 28, 2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM portfolio company Swixx BioPharma announces EUR 45 million capital increase | Swixx BioPharma, a privately held company in the portfolio of HBM Healthcare Investments, today announced the signing of an investment agreement with Mérieux Equity Partners and its existing shareholders. Under the terms of the agreement, M... |
| May 28, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : portfolio company Swixx BioPharma announces EUR 45 million capital increase | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Capital Increase
HBM portfolio company Swixx BioPharma announces EUR 45 million capital increase
28-May-2021 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. ... |
| May 28, 2021 | HBM Healthcare Investments : portfolio company Swixx BioPharma announces EUR 45 million capital increase | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Capital Increase
HBM portfolio company Swixx BioPharma announces EUR 45 million capital increase
28-May-2021 / 07:15 CET/CEST
Release of an ad hoc announcement pursuant to Art. ... |
| May 21, 2021 | Swixx BioPharma secures close to €100 million to fuel its growth | The strong Swiss pharma and biotech cluster includes not only drug development companies but also service providers. Among them are fast growing companies such as Zug-based Swixx BioPharma which was founded under the name Amicus in 2013.
Sw... |
| May 21, 2021 | Swixx BioPharma secures close to €100 million to fuel its growth | |
| May 7, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a total of CHF 12.50 per share. | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Annual Results
HBM Healthcare Investments reports a profit of CHF 756 million for the 2020/2021 financial year; Increase of the proposed cash distribution to a total of CHF 12.5... |
| Apr 6, 2021 | Mineralys Therapeutics Closes $40 Million Series A Funding | Aldosterone has been implicated as an underlying cause of hypertension in upwards of 30 percent of all hypertension patients and as such represents an ideal target for therapeutic intervention in these patients. In a Phase 1 study in health... |
| Apr 1, 2021 | Ad hoc announcement pursuant to Art. 53 Listing RulesHBM Healthcare Investments closes anniversary year with record profit of over CHF 750 million | HBM Healthcare Investments will close its 20th financial year, ending on 31 March 2021, with a record result. The net asset value per share (NAV) rose by 52 percent to CHF 309.25. The share price climbed disproportionately by 79 percent to ... |
| Mar 22, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)
22-March-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant... |
| Mar 22, 2021 | HBM Healthcare Investments : IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%) | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)
22-March-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant... |
| Mar 15, 2021 | HBM Healthcare Investments : Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals
15-March-2021 / 06:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. ... |
| Mar 15, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): IPO
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals
15-March-2021 / 06:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. ... |
| Jan 22, 2021 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments : Quarterly Report December 2020 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments Quarterly Report December 2020
22-Jan-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is sol... |
| Jan 22, 2021 | HBM Healthcare Investments : Quarterly Report December 2020 | EQS Group-Ad-hoc: HBM Healthcare Investments AG / Key word(s): Quarter Results
HBM Healthcare Investments Quarterly Report December 2020
22-Jan-2021 / 06:45 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is sol... |
| Oct 9, 2020 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments Media Release | Media Release
Zug, 9 October 2020
Successful IPO of Everest Medicines on the Hong Kong Stock Exchange
Everest Medicines (symbol: 1952 HK), a privately held company in the portfolio of HBM Healthcare Investments, today completed its announce... |
| Oct 5, 2020 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments Media Release | Media Release
Zug, 5 October 2020
HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share
C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of H... |
| Oct 5, 2020 | HBM portfolio company C4 Therapeutics raises USD 182 million in initial public offering; marginal positive impact on NAV per HBM share | C4 Therapeutics (Nasdaq: CCCC), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 182 million in new capital by issuing 9.6 million shares at a price of USD 19.00... |
| Sep 16, 2020 | Polyneuron Extends Series A to CHF36.5 Million | |
| Sep 16, 2020 | Polyneuron Extends Series A to CHF36.5 Million | Polyneuron will use the proceeds to advance its lead product candidate PN-1007, a potential treatment for anti-MAG neuropathy, a serious nervous system disease with a high unmet medical need, through Phase I/IIa clinical development. Clinic... |
| Jul 27, 2020 | HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share | iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio of HBM Healthcare Investments, completed its planned IPO last Friday. The company raised USD 201 million in new capital by issuing 10.6 million shares at a price of USD 1... |
| Jul 27, 2020 | HBM HEALTHCARE INVESTMENTS AG
HBM Healthcare Investments Media Release | Media Release
Zug, 27 July 2020
HBM portfolio company iTeos Therapeutics raises USD 201 million in initial public offering; marginal positive impact on NAV per HBM-share
iTeos Therapeutics (Nasdaq: ITOS), a private company in the portfolio ... |
| Jun 17, 2019 | HBM Healthcare Investments announces investment of USD 20 million in Viela Bio | Viela Bio, a privately held biotechnology company, today announced the successful completion of a USD 75 million private placement. HBM Healthcare Investments led the financing round and invested USD 20 million. Additional new investors inc... |
| Sep 5, 2018 | HBM Healthcare Investments takes USD 15 million stake in China's Leading Online Pharmacy and Healthcare Services Platform Jianke | Jianke, a privately held company based in Guangzhou, China, today announced the closing of a USD 130 million financing round. HBM Healthcare Investments participated with USD 15 million in this financing. |
| Mar 29, 2018 | Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million | |
| Oct 20, 2017 | BaseHealth Lands $8.5M for Predictive Analytics Platform to Uncover ‘Invisible Patients’ | BaseHealth, a predictive, evidence-based, and data-driven population health management solution that targets the unknown risk by identifying the “Invisible Patients” has raised $8.5 million in Series C funding led by HBM Healthcare Investme... |
| Oct 18, 2017 | BaseHealth raises $8.5M with an eye to pinpointing at-risk patients | Founded in 2011, BaseHealth takes an analytics-based approach to population health. Its predictive health platform gives organizations the information needed to identify patients at risk for 43 chronic diseases. Ultimately, the startup seek... |
| Oct 6, 2017 | HBM Healthcare Investments announces investment of USD 30 million in Harmony Biosciences | |
| Apr 28, 2017 | HBM invests EUR 20 million in Amicus | |
| May 31, 2016 | India: 1mg raises funds from HBM Healthcare | Premium
Online healthcare start-up 1mg Technologies Pvt. Ltd on Monday said it has raised undisclosed additional funding in its Series B round from global healthcare-focused fund HBM Healthcare Investments AG.
Continue reading this story wi... |
| May 18, 2016 | HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite a negative market environment. Unchanged cash dividend of CHF 5.50 per share. | |
| Apr 1, 2016 | HBM Healthcare Investments closes financial year 2015/2016 with earnings of CHF 23 million despite pronounced market correction in healthcare sector | |
| Nov 24, 2015 | ObsEva Closes CHF 60 Million in Series B Financing | |
| Nov 23, 2015 | Daily funding roundup - November 23, 2015 | ColorChip raised $25M; Quizlet secured $12M; Sportpursuit received $14.4M funding
South Korean apartment cleaning service WaHome has received $1 million in a seed investment from Sparklabs Global Ventures, Mashup Angels, Fast Track Asia and... |
| Nov 23, 2015 | HBM Healthcare Investments participates in CHF 60 million financing of Swiss women’s health company ObsEva | |
| Jun 30, 2015 | HBM Healthcare Investments announces the issue of two bond tranches, one with a 6 year and the other with a 8 year term with a minimum issue amount of CHF 50 million each | |
| Oct 28, 2014 | HBM Healthcare Investments takes USD 8 million stake in Vascular Dynamics | |
| Feb 17, 2014 | HBM Healthcare Investments participates with EUR 20 million in financing round of Advanced Accelerator Applications | |
| Nov 6, 2013 | Delenex Therapeutics closes CHF 7.3 Million Series A3 Financing | |
| May 10, 2013 | HBM Healthcare plans to invest in private companies again | |
| Jul 23, 2012 | Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | With cystic fibrosis the goal is to improve lung function and reduce pulmonary exacerbation. In a Phase 3 clinical study, Ataluren demonstrated trends in improvement in lung function when compared to a placebo. There were also trends in imp... |
| BaseHealth raises $8.5M with an eye to pinpointing at-risk patients | Sunnyvale, California-based BaseHealth has closed an $8.5 million Series C funding round, according to a news release.
The round includes $2.5 million from lead investor HBM Healthcare Investments. Other investors weren’t disclosed in the r... |
| Late-stage cystic fibrosis, muscular dystrophy drug raises $30 million | A biopharmaceutical company with a cystic fibrosis drug in late-stage development has raised $30 million, according to a company statement. It was about $10 million less than the original funding target listed in a form D document with the ... |